Earnings Call · Q1 FY2024·2024-05-10

Q2 21EPS n/a·Rev n/aQ1 21EPS n/a·Rev n/aQ4 20EPS n/a·Rev n/aQ2 20EPS n/a·Rev n/a⚠ consensus missing

Humacyte, Inc. HUMAW

Thomas Johnson — Investor Relations or Communications

Turning now to our program in dialysis access. In March of 2024, we hosted a key opinion leader webinar entitled Hemodialysis Care

Dale Sander — CFO

−2.3%1d on move date−2.4% vs SPY3d+60.6%5d+74.0%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more HUMAW calls or request research access.

More HUMAW calls Browse calls Request research access